Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

38 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Advancing Drug Development in Myelodysplastic Syndromes.
Mina A, McGraw KL, Cunningham L, Kim N, Jen EY, Calvo KR, Ehrlich LA, Aplan PD, Garcia-Manero G, Foran JM, Garcia JS, Zeidan AM, DeZern AE, Komrokji RS, Sekeres MA, Scott BL, Buckstein RJ, Tinsley-Vance S, Verma A, Wroblewski T, Pavletic SZ, Norsworthy KJ. Mina A, et al. Among authors: norsworthy kj. Blood Adv. 2024 Dec 30:bloodadvances.2024014865. doi: 10.1182/bloodadvances.2024014865. Online ahead of print. Blood Adv. 2024. PMID: 39786387
FDA Approval Summary: Olutasidenib for Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with an Isocitrate Dehydrogenase 1 Mutation.
Woods AC, Norsworthy KJ, Choe M, Gehrke BJ, Chen H, Vallejo J, Pan L, Jiang X, Li H, Kraft J, Liu J, Charlab R, Okusanya OO, Booth B, Pazdur R, Theoret MR, Angelo de Claro R. Woods AC, et al. Among authors: norsworthy kj. Clin Cancer Res. 2025 Jan 6;31(1):12-17. doi: 10.1158/1078-0432.CCR-24-2196. Clin Cancer Res. 2025. PMID: 39475462
Perspectives on Drug Development for the Treatment of Chronic Myeloid Leukemia in Pregnant Patients and Patients Who Are Breastfeeding.
Cortes JE, Abruzzese E, Cardonick EH, Hernández-Díaz S, Gutierrez J, Sardegna MS, Torres-Chavez E, Dinatale M, Lerro CC, Gehrke BJ, Shord SS, De Claro RA, Theoret MR, DeMaria PJ, Norsworthy KJ. Cortes JE, et al. Among authors: norsworthy kj. Clin Cancer Res. 2024 Sep 3;30(17):3658-3666. doi: 10.1158/1078-0432.CCR-24-0826. Clin Cancer Res. 2024. PMID: 38967550 Review.
Project Confirm: Accelerated Drug Approvals for CML-Response.
Sweet KL, Cortes JE, Apperley JF, Mann M, Mauro MJ, Oehler VG, Ruiz C, Schiffer CA, Ehrlich LA, Pamuk GE, Wynne J, Mehta GU, Okusanya OO, de Claro RA, Theoret MR, Smith BD, Norsworthy KJ. Sweet KL, et al. Among authors: norsworthy kj. Clin Cancer Res. 2024 Jan 5;30(1):237-238. doi: 10.1158/1078-0432.CCR-23-3234. Clin Cancer Res. 2024. PMID: 38178776 Free PMC article. No abstract available.
FDA Approval Summary: Ivosidenib in Combination with Azacitidine for Treatment of Patients with Newly Diagnosed Acute Myeloid Leukemia with an IDH1 Mutation.
Woods A, Norsworthy KJ, Wang X, Vallejo J, Chiu Yuen Chow E, Li RJ, Sun J, Charlab R, Jiang X, Pazdur R, Theoret MR, de Claro RA. Woods A, et al. Among authors: norsworthy kj. Clin Cancer Res. 2024 Apr 1;30(7):1226-1231. doi: 10.1158/1078-0432.CCR-23-2234. Clin Cancer Res. 2024. PMID: 38010220 Free PMC article. Clinical Trial.
38 results